131 related articles for article (PubMed ID: 11926128)
1. Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy--clinical progress.
Renhowe PA
Curr Opin Drug Discov Devel; 2002 Mar; 5(2):214-24. PubMed ID: 11926128
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, Kit, platelet-derived growth factor receptor, Ras.
Erman M
J BUON; 2007 Sep; 12 Suppl 1():S83-94. PubMed ID: 17935283
[TBL] [Abstract][Full Text] [Related]
3. Growth factor receptors: implications in tumor biology.
Srinivasan DM; Kapoor M; Kojima F; Crofford LJ
Curr Opin Investig Drugs; 2005 Dec; 6(12):1246-9. PubMed ID: 16370390
[TBL] [Abstract][Full Text] [Related]
4. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents.
Morin MJ
Oncogene; 2000 Dec; 19(56):6574-83. PubMed ID: 11426642
[TBL] [Abstract][Full Text] [Related]
5. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
6. Targeting protein kinases in cancer therapy.
Fabbro D; García-Echeverría C
Curr Opin Drug Discov Devel; 2002 Sep; 5(5):701-12. PubMed ID: 12630290
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
8. Flavonoids as RTK inhibitors and potential anticancer agents.
Teillet F; Boumendjel A; Boutonnat J; Ronot X
Med Res Rev; 2008 Sep; 28(5):715-45. PubMed ID: 18080331
[TBL] [Abstract][Full Text] [Related]
9. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
10. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
11. Novel anticancer drug discovery.
Buolamwini JK
Curr Opin Chem Biol; 1999 Aug; 3(4):500-9. PubMed ID: 10419854
[TBL] [Abstract][Full Text] [Related]
12. Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases.
Hubbard RD; Bamaung NY; Fidanze SD; Erickson SA; Palazzo F; Wilsbacher JL; Zhang Q; Tucker LA; Hu X; Kovar P; Osterling DJ; Johnson EF; Bouska J; Wang J; Davidsen SK; Bell RL; Sheppard GS
Bioorg Med Chem Lett; 2009 Mar; 19(6):1718-21. PubMed ID: 19217287
[TBL] [Abstract][Full Text] [Related]
13. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
Cascone T; Gridelli C; Ciardiello F
Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
[TBL] [Abstract][Full Text] [Related]
14. Receptor tyrosine kinase inhibitors.
Haluska P; Adjei AA
Curr Opin Investig Drugs; 2001 Feb; 2(2):280-6. PubMed ID: 11816845
[TBL] [Abstract][Full Text] [Related]
15. Novel combinations based on epidermal growth factor receptor inhibition.
Adjei AA
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4446s-4450s. PubMed ID: 16857826
[TBL] [Abstract][Full Text] [Related]
16. Targeting growth factors and angiogenesis; using small molecules in malignancy.
Wanebo HJ; Argiris A; Bergsland E; Agarwala S; Rugo H
Cancer Metastasis Rev; 2006 Jun; 25(2):279-92. PubMed ID: 16770540
[TBL] [Abstract][Full Text] [Related]
17. Growth factors as active participants in carcinogenesis: a perspective.
Halper J
Vet Pathol; 2010 Jan; 47(1):77-97. PubMed ID: 20080487
[TBL] [Abstract][Full Text] [Related]
18. Targeted agents for the treatment of advanced renal cell carcinoma.
Stadler WM
Cancer; 2005 Dec; 104(11):2323-33. PubMed ID: 16240452
[TBL] [Abstract][Full Text] [Related]
19. Control of PDGF-induced reactive oxygen species (ROS) generation and signal transduction in human lens epithelial cells.
Chen KC; Zhou Y; Zhang W; Lou MF
Mol Vis; 2007 Mar; 13():374-87. PubMed ID: 17392688
[TBL] [Abstract][Full Text] [Related]
20. Key cancer cell signal transduction pathways as therapeutic targets.
Bianco R; Melisi D; Ciardiello F; Tortora G
Eur J Cancer; 2006 Feb; 42(3):290-4. PubMed ID: 16376541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
